Digestive Oncology Unit, University Hospital Gasthuisberg, Herestraat 49, Leuven, Belgium.
Ann Oncol. 2010 Jun;21 Suppl 6:vi1-10. doi: 10.1093/annonc/mdq273.
The article summarizes the expert discussion and recommendations on the use of molecular markers and of biological targeted therapies in metastatic colorectal cancer (mCRC), as well as a proposed treatment decision strategy for mCRC treatment. The meeting was conducted during the 11th ESMO/World Gastrointestinal Cancer Congress (WGICC) in Barcelona in June 2009. The manuscript describes the outcome of an expert discussion leading to an expert recommendation. The increasing knowledge on clinical and molecular markers and the availability of biological targeted therapies have major implications in the optimal management in mCRC.
本文总结了在转移性结直肠癌(mCRC)中使用分子标志物和生物靶向治疗的专家讨论和建议,以及提出的 mCRC 治疗决策策略。该会议于 2009 年 6 月在巴塞罗那举行的第 11 届 ESMO/世界胃肠道癌大会(WGICC)上进行。本文描述了一次专家讨论的结果,该讨论促成了一项专家建议。临床和分子标志物的知识不断增加以及生物靶向治疗的出现,对 mCRC 的最佳治疗管理具有重大意义。